Drugs / American ginseng
American ginseng
also known as
Ginseng · American Ginseng root · Panax Quinquefolius · AFX-2 · Ginsana · ginseng extract · HT-1001 · NAG · +2 more
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT03407716 | Mar 2019 → May 2020 | breast carcinoma, colorectal carcinoma | Mayo Clinic | Completed | No outcome recorded |
| Phase 0 | NCT02386852 | Mar → Nov 2014 | — | Sunway University | Completed | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT01456182 | Dec 2011 → Mar 2013 | B-cell chronic lymphocytic leukemia | Afexa Life Sciences Inc | Withdrawn | No outcome recorded |
| Phase 1 | NCT01136928 | Sep 2010 → Mar 2011 | — | Johns Hopkins University | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT00631852 | Feb 2008 → Jun 2019 | breast cancer | Southern Illinois University | Completed | No outcome recorded |
| Phase 2 | NCT00754832 | Sep 2005 → Sep 2008 | multiple sclerosis | Oregon Health and Science University | Completed | No outcome recorded |
| Phase 2 | NCT00029692 | Mar 2002 → Mar 2005 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT06395441 | Aug 2024 → Nov 2026 expected | cancer | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 3 | NCT00719563 | Oct 2008 → Aug 2011 | cancer of unknown primary site, leukemia, lymphoproliferative syndrome, myelodysplastic syndrome +4 | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT00367926 | Jun → Jul 2005 | hyperglycemia | Risk Factor Modification Centre | Completed | No outcome recorded |
| Phase 3 | NCT00219960 | Apr 2001 → Oct 2003 | hypertensive disorder | Risk Factor Modification Centre | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT00781534 Comparator | Sep 2003 → Dec 2004 | diabetes mellitus | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01500096 Comparator | Feb 2013 → Sep 2016 | AIDS-related disorder | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT01712373 Comparator | Dec 2010 → Apr 2011 | — | Isfahan University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | American ginseng | “Dietary Supplement: American Ginseng” NCT06395441 ↗ |
| Known as | AFX-2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01456182 ↗ |
| Known as | American Ginseng root | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00631852 ↗ |
| Known as | Ginsana | “1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos.” NCT00029692 ↗ |
| Known as | Ginseng | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00029692 ↗ |
| Known as | ginseng extract | “1) ginseng extract (Ginsana), 2) ginkgo extract (Egb761), 3) both herbs, or 4) matching placebos.” NCT00029692 ↗ |
| Known as | HT-1001 | “Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated.” NCT00754832 ↗ |
| Known as | NAG | “North American ginseng (NAG)” NCT00219960 ↗ |
| Known as | North American Ginseng | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00219960 ↗ |
| Known as | Panax Ginseng | “The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo...” NCT02386852 ↗ |
| Known as | Panax Quinquefolius | “To evaluate the efficacy of American ginseng (Panax quinquefolius) as therapy for cancer-related fatigue as measured by the general subscale of the Multidimensional Fatigue...” NCT00719563 ↗1“North American Ginseng (Panax Quinquefolius)” NCT00219960 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “The World Health Organization lists ginseng as a traditional medicine with very low toxicity.” NCT00631852 ↗ |
| Route | Oral | “Given orally” NCT00719563 ↗ |